Full Text | PDF

Theranostics 2024; 14(1):249-264. doi:10.7150/thno.87306 This issue Cite

Research Paper

Reprogramming of endothelial gene expression by tamoxifen inhibits angiogenesis and ERα-negative tumor growth

Chanaëlle Fébrissy¹, Marine Adlanmerini¹, Christel Péqueux², Frédéric Boudou¹, Mélissa Buscato¹, Adrien Gargaros¹, Silveric Gilardi-Bresson¹, Khrystyna Boriak¹, Henrik Laurell¹, Coralie Fontaine¹, Benita S. Katzenellenbogen³, John A. Katzenellenbogen³, Julie Guillermet-Guibert⁴, Jean-François Arnal¹, Raphaël Metivier⁵, Françoise Lenfant^1✉

1. INSERM U1297, Institut des Maladies Métaboliques et Cardiovasculaires, Université de Toulouse, BP 84225, 31 432 Toulouse cedex 04, France.
2. Laboratoire de Biologie des Tumeurs et du Développement, GIGA-Cancer, Université de Liège, B23, Liège, Belgium.
3. Departments of Molecular and Integrative Physiology and Chemistry, University of Illinois, Urbana, Illinois, USA.
4. INSERM U1037, CRCT, Oncopole- 31 037 Toulouse cedex, France.
5. Institut de Génétique De Rennes (IGDR). UMR 6290 CNRS-Université de Rennes, ERL INSERM U1305. CS 74205- 35042 Rennes Cedex, France.

✉ Corresponding author: Françoise Lenfant, Ph.D. INSERM U1297, Institut des Maladies Métaboliques et Cardiovasculaires, Université de Toulouse UT3, CHU Rangueil, 1 avenue J. Poulhès, BP 84225, 31 432 Toulouse cedex 04, France, T33;l : (33)-(0)5-31-22-40-93, e-mail : Francoise.Lenfantfr. More

Abstract

Rationale: 17β-estradiol (E2) can directly promote the growth of ERα-negative cancer cells through activation of endothelial ERα in the tumor microenvironment, thereby increasing a normalized tumor angiogenesis. ERα acts as a transcription factor through its nuclear transcriptional AF-1 and AF-2 transactivation functions, but membrane ERα plays also an important role in endothelium. The present study aims to decipher the respective roles of these two pathways in ERα-negative tumor growth. Moreover, we delineate the actions of tamoxifen, a Selective Estrogen Receptor Modulator (SERM) in ERα-negative tumors growth and angiogenesis, since we recently demonstrated that tamoxifen impacts vasculature functions through complex modulation of ERα activity.

Methods: ERα-negative B16K1 cancer cells were grafted into immunocompetent mice mutated for ERα-subfunctions and tumor growths were analyzed in these different models in response to E2 and/or tamoxifen treatment. Furthermore, RNA sequencings were analyzed in endothelial cells in response to these different treatments and validated by RT-qPCR and western blot.

Results: We demonstrate that both nuclear and membrane ERα actions are required for the pro-tumoral effects of E2, while tamoxifen totally abrogates the E2-induced in vivo tumor growth, through inhibition of angiogenesis but promotion of vessel normalization. RNA sequencing indicates that tamoxifen inhibits the E2-induced genes, but also initiates a specific transcriptional program that especially regulates angiogenic genes and differentially regulates glycolysis, oxidative phosphorylation and inflammatory responses in endothelial cells.

Conclusion: These findings provide evidence that tamoxifen specifically inhibits angiogenesis through a reprogramming of endothelial gene expression via regulation of some transcription factors, that could open new promising strategies to manage cancer therapies affecting the tumor microenvironment of ERα-negative tumors.

Keywords: Tamoxifen, Angiogenesis, Estrogen Receptor ERα, Endothelial cells, Tumor growth

Citation styles

©2024 Ivyspring International Publisher. Terms of use